0O9B Stock Chart & Stats
€10.32
-€0.04(-0.52%)
At close: 4:00 PM EST
€10.32
-€0.04(-0.52%)
Day’s Range― - ―
52-Week Range€9.89 - €13.98
Previous CloseN/A
Volume457.00
Average Volume (3M)27.80K
Market Cap
€2.29B
Enterprise Value€2.41K
Total Cash (Recent Filing)€355.41M
Total Debt (Recent Filing)€363.67M
Price to Earnings (P/E)31.6
Beta0.97
Next Earnings
Nov 09, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.33
Shares Outstanding217,777,330
10 Day Avg. Volume57,725
30 Day Avg. Volume27,803
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.39
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability ReboundThe sharp TTM revenue acceleration and return to profitability indicate materially improved operating performance. If the stronger sales base persists, Almirall can generate greater resources for commercial execution, product development, and portfolio expansion across medical dermatology.
Conservative Balance SheetDeclining leverage alongside a growing equity base provides financial resilience and preserves flexibility for investment in branded medicines, lifecycle management, or partnerships. A conservative capital structure also reduces pressure on cash flows when operating results fluctuate.
Strengthened Cash GenerationStrong TTM operating and free cash flow improves Almirall’s ability to fund research, commercialization, and other strategic priorities internally. Better cash generation can also support balance-sheet stability and reduce reliance on external financing for growth.
Bears Say
Earnings VolatilityThe uneven multi-year earnings record makes it harder to establish that the recent improvement is a durable earnings base. Continued volatility could complicate planning, reduce confidence in sustainable margins, and limit the predictability of shareholder returns.
Inconsistent Cash Flow QualityAlthough TTM cash generation is strong, the prior inconsistency shows that reported improvement has not yet translated into a reliably repeatable cash profile. Uneven conversion can constrain internally funded investment during weaker operating periods.
Low Returns On CapitalMid-single-digit returns on the shareholder capital base suggest profitability remains modest relative to the resources deployed. Unless returns improve, Almirall may have less capacity to compound value efficiently even if revenue and absolute cash flow continue growing.
Almirall News
0O9B FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest share price was €9.89 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.29B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is Nov 09, 2026 which is in 44 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Jul 24, 2026. The company reported €0.112 earnings per share for the quarter, missing the consensus estimate of €0.13 by -€0.018.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Overvalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate is 0.13.
How many shares outstanding does Almirall SA have?
Almirall SA has 217,777,330 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.112 in its last earnings report, missing expectations of €0.13. Following the earnings report the stock price went up 1.989%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in GB:0O9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.95%
12-Months-Change
Fundamentals
Return on Equity
1.74%
Trailing 12-Months
Asset Growth
2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Almirall SA
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.